ActiBreast Breast Enhancing Cream with Lipofilling Effect
Effect Mechanism
Lipofilling is a surgical technique to inject fat in parts of the body that need volume.
Is it possible to achieve lipofilling without surgery?
Owing to its special formula, ActiBreast promotes body volume by a cosmetic lipofilling-like effect without surgery.
 | The importance of fat for the breast size
The volume and shape of the breasts are determined by the quantities of
glandular and adipose tissue that they contain. Thus, generally between the age of
30 and 50 years, the breast consists in adipose tissue, which constitutes one half of
its volume, and mammary gland, which constitutes the other half.
The subcutaneous fat that forms an external mantel
over the mammary gland, is a potential target for amplifying the curvature of
the breasts and restoring the shapeliness of the décolleté. |
The effect of the patented active component over adipocyte (fat cells) is proved by scientific experiments.
Phytosterol with no hormonal activity:
- Stimulates adipocyte proliferation and differentiation.
- Promotes lipid storage.
- Increase of adipocyte volume in the fatty tissue.
- Can be applied on breast, buttock, hands or cheeks.
| Differentiation | | Maturation
|
Mechanism of action elucidated by DNA array:
Adipocyte differentiation:
1- Stimulation of MAX binding protein and PPAR way
Lipid storage:
2- Stimulation of Adipophilin protein responsible of fatty acid chain and lipid droplet formation.
3- Stimulation of SLC2A5/GLUT5 involved in the transport of fructose into the adipocyte.
|
Properties of the active component:
Function: Promotes body volume by a cosmetic
lipofilling-like effect.
Definition: The active component is extracted from the
roots of a botanical plant, in an oil-soluble
excipient. Preservative free.
Properties: Stimulates adipocyte
differentiation and proliferation, and
promotes lipid storage leading to an
increase of adipocyte volume in the
fatty tissue.
The mechanism of action of the active component is elucidated by
DNA-array technique. It
activates the differentiation pathway
(PPARã,COPS3, COPS5), stimulates
lipid incorporation through the
glucose/fructose pathway (adipophilin,
SLC2A5, GLUT5) and promotes fatty
tissue setting among the extra cellular
matrix (LOX, ECM2).
It increases:
- Pre-adipocyte differentiation (with measurement of the differentiation marker G3PDH activity) 201%
- Adipocyte proliferation 32%
- Lipid storage 641%
- Adipocyte volume X22 times
| The 28-day active component experiment results which show increase in adipocyte volume |
 
|
Clinical Studies
The active component of ActiBreast is experienced by FOITS method.
FOITS is a touch-free technique that allows three-dimensional information to be gathered from the surface of the skin in an extremely short time.
FOITS Method
  |
Study type:
Single-blind controlled study, treated breast vs. untreated breast.
The treated breast was the left or right breast (randomization of the study
population). 30 completed the study.
Special study criteria:
- Women aged 18 to 35 years
- Small breast volume, cup size 80-85B or 90A
- Body weight stable for at least 3 months.
- Regular hormonal status or status stabilized by oral contraceptives. No pregnancy
or breast-feeding during the study.
Application of the active component:
Applied twice daily for 56 days.
| Treated side
breast volume (mm3) | Untreated side
breast volume (mm3) |
| Day 0 | 5000 | 5000 |
| Day 28 | 5070 (1,4%) | 4997 (-0,1%) |
| Day 56 | 5108 (2,2%) | 5046 (-0,9%) |
Best responders at Day 28
(8 women) | 5330 (6,6%) | 4900 (-6,6%) |
Best responders at Day 56
(8 women) | 5420 (8,4%) | (-2,0%) |
In order to facilitate result reading, the volumes at Day 0 were normalized on a
reference value of 5000 mm3.
The breast volume determined by FOITS method.
The percentage increases for the responders are seen as below:
3% after 28 days,
over 8,4% after 28 days
The graphics show real experiment results.
|
|
By applying the product during 6 months, a woman with cup size A (about 300 cc) can gain in volume up to 81 cc in each breast which corresponds to 30% increase.
REFERENCES
GREGOIRE FM, SMAS CM and SUL HS, 1998
Understanding Adipocyte differentiation
Physiological Reviews, 78 (3), p 783-809
ROSEN ED, WALKEY CJ, PUIGSERVER P, and SPIEGELMAN BM, 2000
Transcriptional regulation of adipogenesis
Genes & Development, 14 p1293-1307
Eur J Pharmacol. 2000 May 26; 397(1):187-95.
SHI H, HALVORSEN YD, ELLIS PN, WILKISON WO, and ZEMEL MB, 2000
Role of intracellular calcium in human adipocyte differentiation
Physiological genomics, 3, p75-82.
|
